Real World Environmental Exposure Study With Healthy & Cystic Fibrosis

Status Not yet recruiting

Clinical Trial Summary

Cystic fibrosis (CF) is the most common autosomal recessive disease that leads to early mortality in Caucasians and affects around 7500 patients in France. Progression of the disease depends on pulmonary exacerbations defined as acute deterioration of respiratory symptoms which ultimately impair lung function and quality of life. Most frequently caused by lung bacterial infections, exacerbations' effects include increased cough, increased sputum production, increased use of antibiotics, dyspnea and decreased lung function. The phenotypic variability of CF suggests the implication of other contributors especially to the CF airway disease. Beside genetic and epigenetic alterations, environmental factors - e.g tobacco smoke, air pollution, temperature changes, food intake - appear as relevant candidates. A previous review has discussed current knowledge on the effects of air pollution on the course of CF disease. Although scarce, the existing epidemiological andexperimental literature suggests a link between exposure to air pollutants and adverse health effects.Although scarce, the existing epidemiological and experimental literature suggests a link between exposure to air pollutants and adverse health effects. The EU sponsored REMEDIA project (Impact of exposome on the course of lung diseases, Grant agreement ID 874753) contributes to the understanding of the influence of the exposome on chronic obstructive pulmonary disease (COPD) and CF. Objective of work package 3 within the REMEDIA project is the development of a mobile environmental sensor toolbox that is capable to assess the external exposome. The biomarkertoolbox was developed and tested in a proof-of-concept study carried out in healthy volunteers. The next step is to validate the collectionof exhaled breath condensate (EBC) in a real-life study. In this aim, the objective of the present study will be to assess the feasibility of EBC collection in CF patients and healthy individuals

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06339450
Study type	Interventional
Source	Centre Hospitalier Intercommunal Creteil
Contact	camille Jung
Phone	0157022268
Email	camille.jung@chicreteil.fr
Status	Not yet recruiting
Phase	N/A
Start date	May 1, 2024
Completion date	December 31, 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05541653` - The IGNITE Study on Concentrated Investment in Black Neighborhoods	N/A
Completed	`NCT04028791` - Sickle Cell Trait and Exercise, Effect of Hot Environment	N/A
Not yet recruiting	`NCT05105386` - The Impact of Synergies of Indoor Air Pollutants on Childhood Health and Wellbeing
Completed	`NCT05507944` - FeNO Hairdressers Pilot
Completed	`NCT04146025` - Nurtured in Nature	N/A
Recruiting	`NCT05179993` - Detection of Microplastics in Human Granulosa Cells and in the Follicular Fluid of Women Undergoing ICSI Treatment
Completed	`NCT03444922` - Effects of BPA on Insulin and Glucose Responses	N/A
Recruiting	`NCT03319927` - Reducing Pesticide Exposures in Child Care Centers	N/A
Recruiting	`NCT05500690` - Understanding Effects of Folic Acid on the Methylosome and Transcriptome of Women With Spina Bifida Affected Pregnancies	N/A
Recruiting	`NCT05394363` - Generation Victoria Cohort 2020s: A Statewide Longitudinal Cohort Study of Victorian Children and Their Parents
Completed	`NCT00021658` - Effects of Pesticide Exposure on Neurodevelopment/Growth/Respiratory Health	N/A
Not yet recruiting	`NCT05315388` - Effects of "Vitamin N" Nature Immersion Therapy on Stress Levels in Health Care Workers in the City of Bogotá	N/A
Recruiting	`NCT06107933` - Developmental Impacts of Microplastics Exposure in Early Life
Completed	`NCT03631667` - Ultralow Dose PAH Binary Mixture Study	Early Phase 1
Completed	`NCT02540408` - Detection and Characterization of COPD in Dairy Farmers	N/A
Completed	`NCT03440307` - Intervention to Reduce Bisphenol A Exposure in Women	N/A
Completed	`NCT05160948` - Change in Knowledge After Receiving Personal Air Pollution Results
Not yet recruiting	`NCT05865782` - Reconstructing Schoolyards With Greenery to Increase Schoolchildren's Physical Activity and Mitigate Climate Changes	N/A
Completed	`NCT02707172` - Removal of Dermal Exposure to Phthalate Ester by Hand Washing	N/A
Active, not recruiting	`NCT03215368` - The Ma'Anshan Birth Cohort (MABC)

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Real World Environmental Exposure Study With Healthy and Cystic Fibrosis Subjects — ExpoCF

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms